Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 4
2011 1
2013 1
2014 2
2015 1
2016 4
2017 2
2018 2
2019 4
2020 2
2021 2
2022 3
2023 2
2024 2
2025 8

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

32 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, Ho PJ, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Gay F, Mina R, Nijhof IS, van de Donk NWCJ, Katodritou E, Schjesvold F, Sureda Balari A, Rosiñol L, Delforge M, Roeloffzen W, Silzle T, Vangsted A, Einsele H, Spencer A, Hajek R, Jurczyszyn A, Lonergan S, Ahmadi T, Liu Y, Wang J, Vieyra D, van Brummelen EMJ, Vanquickelberghe V, Sitthi-Amorn A, de Boer CJ, Carson R, Rodriguez-Otero P, Bladé J, Moreau P; PERSEUS Trial Investigators. Sonneveld P, et al. N Engl J Med. 2024 Jan 25;390(4):301-313. doi: 10.1056/NEJMoa2312054. Epub 2023 Dec 12. N Engl J Med. 2024. PMID: 38084760 Clinical Trial.
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
De Novellis D, Derudas D, Vincelli D, Fontana R, Della Pepa R, Palmieri S, Accardi F, Rotondo F, Morelli E, Gigliotta E, Roccotelli D, Marano L, Barone ML, Cetani G, Esposito D, Lazzaro A, Delle Cave G, Serio B, Morini D, Porrazzo M, Urciuoli E, Masucci C, Fanelli F, Rizzo M, Arcamone M, Trastulli F, Rocco S, Leone A, Bianco R, Salvatore F, Idato A, Sicari M, Tosi P, Rascato MG, Di Perna M, Falcone AP, Morello L, Carlisi M, Svanera G, Annunziata M, Frigeri F, Califano C, Carella AM, Marcacci G, Pane F, Risitano AM, Giudice V, Botta C, Selleri C. De Novellis D, et al. Among authors: falcone ap. Eur J Haematol. 2025 Jan;114(1):105-114. doi: 10.1111/ejh.14314. Epub 2024 Oct 6. Eur J Haematol. 2025. PMID: 39370303 Free PMC article.
Dosing and clinical outcomes of ruxolitinib in patients with myelofibrosis in a real-world setting: Interim results of the Italian observational study (ROMEI).
Breccia M, Palandri F, Martelli M, Mendicino F, Malato A, Palumbo GA, Sibilla S, Di Renzo N, Abruzzese E, Siragusa S, Crugnola M, Selleri C, Pane F, Sportoletti P, Martino B, Impera S, Ricco A, Langella M, Ditonno P, Carli G, Itri F, Liberati AM, Urbano T, Tafuri A, Polizzi V, Pastore D, Morsia E, Benevolo G, Micucci G, Farina G, Bonifacio M, Elli EM, Gardellini A, De Stefano V, Caocci G, Falcone AP, Vallisa D, Brociner M, Tiribelli M, Binotto G, Pocali B, Cavazzini F, Tomassetti S, Lunghi F, Di Ianni M, Allegra A, Anaclerio B, Mazzotta S, Orofino N, Gherlinzoni F, Castiglioni C, Landoni M, Valsecchi D, Magnoli M, Guglielmelli P, Passamonti F. Breccia M, et al. Among authors: falcone ap. Cancer. 2025 Apr 1;131(7):e35801. doi: 10.1002/cncr.35801. Cancer. 2025. PMID: 40111826 Free PMC article.
Prognostic Significance of +1q Alterations in Relapsed/Refractory Multiple Myeloma Treated With Daratumumab-, Elotuzumab-, and Carfilzomib-Based Triplet Regimens: A Multicenter Real-World Analysis of 635 Patients.
Morabito F, Martino EA, Galli M, Offidani M, Zambello R, Bringhen S, Giuliani N, Califano C, Brunori M, Gagliardi A, Sgherza N, Quinto AM, Barilà G, Belotti A, Cerchione C, Casaluci GM, Fontana R, Bongarzoni V, Tarantini G, Derudas D, Patriarca F, Gozzetti A, Sementa A, Antonioli E, Rago A, Lotti F, De Magistris C, Petrucci MT, Pettine L, Bolli N, Conticello C, Zamagni E, Palmieri S, Musso M, Mele A, Della Pepa R, Vigna E, Bruzzese A, Fazio F, Mina R, Paris L, Vincelli ID, Farina G, Cangialosi C, Mancuso K, Falcone AP, Mele G, Sica A, Morè S, Reddiconto G, Tripepi G, D'Arrigo G, Barbieri E, Quaresima M, Cartia CS, Pezzatti S, Marcatti M, Farina F, Cafro A, Palumbo M, Masoni V, Ferretti VV, Di Raimondo F, Musto P, Neri A, Mangiacavalli S, Gentile M. Morabito F, et al. Among authors: falcone ap. Eur J Haematol. 2025 Jul;115(1):16-28. doi: 10.1111/ejh.14413. Epub 2025 Mar 19. Eur J Haematol. 2025. PMID: 40103518 Free PMC article.
Bortezomib-melphalan-prednisone versus lenalidomide-dexamethasone in elderly patients with multiple myeloma: the Real MM phase IV trial.
Bringhen S, Cani L, Giuliani N, Mangiacavalli S, Benevolo G, Antonioli E, Zambello R, Ria R, Vincelli ID, Ronconi S, More S, Falcone AP, Allegra A, D'Agostino M, Evangelista A, Capra A, Sciorsci E, Curci P, Tosi P, Liberati AM, Cafro AM, Belotti A, Patriarca F, Mannina D, Mancuso K, Cattel F, Ciccone G, Bruno B, Boccadoro M, Larocca A. Bringhen S, et al. Among authors: falcone ap. Haematologica. 2025 Jul 31. doi: 10.3324/haematol.2025.287510. Online ahead of print. Haematologica. 2025. PMID: 40820797 Free article.
Carfilzomib-lenalidomide-dexamethasone versus lenalidomide-dexamethasone in patients with newly diagnosed myeloma ineligible for autologous stem-cell transplantation (EMN20): a randomised, open-label, multicentre, phase 3 trial.
Bringhen S, Cani L, Antonioli E, Derudas D, Fazio F, Larocca A, Ronconi S, Cellini C, Falcone AP, Accardi F, Liberati AM, Galieni P, Belotti A, Cafro AM, Ria R, Benevolo G, Vincelli ID, Mannina D, Lotti F, Bruno B, Marasco V, Mazza R, Tosi P, Rivolti E, Boccadoro M, D'Agostino M. Bringhen S, et al. Among authors: falcone ap. Lancet Haematol. 2025 Aug;12(8):e621-e634. doi: 10.1016/S2352-3026(25)00162-0. Lancet Haematol. 2025. PMID: 40769686 Clinical Trial.
Clinicians' Perspectives and Methodological Application of Fluorescence in situ Hybridization (FISH) to Define Cytogenetic Risk in Multiple Myeloma: An Italian, Real-World, Survey-Based Report From the European Myeloma Network (EMN) Italy.
Cani L, Petrucci MT, Mancuso K, Zambello R, Paris L, Aquino S, Lotti F, Vassallo F, Pescosta N, Quaresima M, Tosi P, Vincelli ID, Ronconi S, Giuliani N, Pisani F, Luppi M, Rizzi R, Mazza R, Rota-Scalabrini D, Cellini C, Mangiacavalli S, Pietrantuono G, Pioltelli ML, Falcone AP, Antonioli E, Belotti A, Morè S, Bruno B, Boccadoro M, D'Agostino M. Cani L, et al. Among authors: falcone ap. Clin Lymphoma Myeloma Leuk. 2025 Sep;25(9):676-683.e11. doi: 10.1016/j.clml.2025.03.011. Epub 2025 Mar 29. Clin Lymphoma Myeloma Leuk. 2025. PMID: 40287351 Free article.
Real-world evidence on the use of daratumumab, bortezomib and dexamethasone (DVd) in lenalidomide-refractory myeloma patients: subgroup analysis of the multicenter retrospective experience by "rete ematologica pugliese".
Mele G, Di Renzo N, Cascavilla N, Carella AM, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Merchionne F, Palazzo G, Palumbo G, Quinto AM, Reddiconto G, Rossini B, Spina A, Sgherza N, Specchia G, Musto P, Pastore D. Mele G, et al. Among authors: falcone ap. Leuk Lymphoma. 2023 Oct;64(10):1715-1718. doi: 10.1080/10428194.2023.2232487. Epub 2023 Jul 7. Leuk Lymphoma. 2023. PMID: 37417467 No abstract available.
Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials.
Martino EA, Conticello C, Zamagni E, Pavone V, Palmieri S, Musso M, Tacchetti P, Mele A, Catalano L, Vigna E, Bruzzese A, Mendicino F, Botta C, Vincelli ID, Farina G, Barone M, Cangialosi C, Mancuso K, Rizziello I, Rocchi S, Falcone AP, Mele G, Reddiconto G, Garibaldi B, Iaccino E, Tripepi G, Gamberi B, Di Raimondo F, Musto P, Neri A, Cavo M, Morabito F, Gentile M. Martino EA, et al. Among authors: falcone ap. Hematol Oncol. 2022 Dec;40(5):1009-1019. doi: 10.1002/hon.3035. Epub 2022 Jun 6. Hematol Oncol. 2022. PMID: 35638723
Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by 'Rete Ematologica Pugliese'.
Mele G, Cascavilla N, Di Renzo N, Guarini A, Mazza P, Melillo L, Pavone V, Tarantini G, Curci P, Falcone AP, Germano C, Mele A, Palazzo G, Palumbo G, Reddiconto G, Rossini B, Specchia G, Musto P, Pastore D. Mele G, et al. Among authors: falcone ap. Ann Hematol. 2022 Aug;101(8):1727-1739. doi: 10.1007/s00277-022-04857-0. Epub 2022 May 19. Ann Hematol. 2022. PMID: 35587825
32 results